A new type of drug can help in low blood pressure in people with uncontrolled high blood pressure, with researchers at the annual meeting of the American College of Cardiology in Chicago on Saturday.
In a decisive stage 2 B clinical trial, patients who took experimental drugs along with experimental drug Lorundrostat to the currently available high blood pressure drugs -Lorundrostat was seen, a decrease in systolic blood pressure (upper number), which was 8 points more than patients seen in a placebo. The study will be published in the New England Journal of Medicine.
“This new potential therapy for hypertension is exciting,” the lead author of the study, Dr. Luke Lafin, Cleveland Clinic’s heart, vascular and blood pressure disorder co-Director at Thoracic Institute. Luke Lafin said. “We do a bad job controlling blood pressure in America”
According to disease control and prevention centers, about half of adults in the US have high blood pressure; Among them, its blood pressure of less than 1 in 4 is under control.
High blood pressure is diagnosed when a person has a blood pressure of 130/80 mm Hg or more. A systolic measurement between 120 and 129 mm HG is considered elevated. A general measurement is 120/80 mm Hg or below.
Uncontrolled hypertension – which is defined by Lafin as a measure of 130/80 mm Hg or higher, even with medication – is associated with high risk of heart attacks, strokes, heart failure and kidney failure.
Among patients taking drugs for high blood pressure, the rate of control is 60% to 70%, Dr. Ajay Kirtane said, a cardiologist and Professor of Medicine at Columbia University Vegelos College of Physicians and Surgeons in New York City, who were not involved in research. It releases 30% to 40% of patients who require another option.
Lorundrostat is for this group of patients. The drug works by blocking the synthesis of the adrenal glands of a hormone called aldosterone synthease inhibitors, which controls the amount of salt made by the body. When aldosterone is reduced, salt levels and therefore blood pressure occurs.
To test the safety and efficacy of Lorundrostat, Lafin and his colleagues recruited 285 adults with uncontrolled high blood pressure, whose average age was 60. More than half of the participants (53%) were black.
Laofin said the most risk in black patients. According to the American Heart Association, about 55% of black adults have high blood pressure.
Director of Hypertension Program at Johns Hopkins Medicine, Dr. Oscar Singolani said that involving so many black patients is “a big, big thing,” given that “African Americans … are more responsible to this route.”
All the patients of the test were already taking a mixture of blood pressure medicines. When the test began, the researchers standardized those treatments by putting all the patients on two or three specific drugs. Three weeks later, he assigned the participants randomly to receive one of the two doses of a placebo or lorundrostat for the next 12 weeks.
At three points, the participants wore blood pressure cuffs for a 24-hour period: initially, four weeks after treatment begins and then in 12 weeks.
Lorundrostat, 50 mg, lower dosage of plus standard drugs saw a decrease of 15.4 points in average systolic blood pressure, while the group that received the Placebo Plus standard drugs saw a decrease of 7.4 marks-so there was 8 marks related to the drug related to blood pressure after accounting for Placebo response.
Increase in dose of medicine did not improve results.
Experts stated that the response of the placebo could be higher, this is most likely due to people having people and attracting the attention of health professionals, making them more intelligent about taking their medicines.
With an 8 -digit deficiency, it says from 170 to 162, “This is the limit where you will see a longevity study in a long -term study,” Dr. Dr. Mount Sinai Faster Heart Hospital Director Dr.. Deepak Bhatt said.
Aldosterone is a new class of synthease inhibitors drugs, some of which are close to considering approval compared to others by food and drug administration, Bhatt said. Another, Baxdrostat, is currently in step 3 tests.
Lorundrostat has shown a promise in three levels of clinical trials required for approval. The final one, phase 3 test, has been completed, although the results have not been published yet, Laughing said. Researchers are working on trials with drug manufacturer mineralis theraputics, which funded the tests.
The drug may be potentially available within 12 to 18 months, Laughing said.
In the trial, patients found lorundrostat, which were more likely than those receiving placebo to develop high potassium levels. Doctors of some patients will need to keep an eye, Bhatt said, because it can cause unusual heart rhythm.
Singolani of Johns Hopkins said that he wants to see long -term studies on new medicine and also those who can compare lorundrostat with a chronic drug that works by blocking the receptor for aldosterone.
